According to a recent LinkedIn post from AMT Medical, the company is bringing in Geert van Gansewinkel as its new Chief Executive Officer. The post highlights his prior experience leading GATT Technologies from early development through CE Mark, FDA approval, and eventual acquisition by Johnson & Johnson.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The LinkedIn post suggests this leadership change is intended to support progress of AMT Medical’s ELANA Heart Bypass System toward key regulatory milestones. Founder Rutger Tulleken is described as continuing in a Strategic Advisor role, which may help preserve relationships with leading cardiac surgeons and maintain continuity in innovation.
By emphasizing a minimally invasive, reproducible coronary bypass procedure accessible worldwide, the post underscores AMT Medical’s focus on scaling a specialized MedTech platform. For investors, the appointment of a CEO with proven regulatory and exit experience could indicate an increased emphasis on value-creating milestones, including potential approvals, partnerships, or strategic transactions over the medium term.